Study of S-1 Plus LV for Advanced Gastric Cancer
The purpose of this study is to evaluate the effectiveness and safety of S-1 plus Leucovorin (1 week on and 1 week off) as first-line treatment for patients with metastatic and recurrent gastric cancer.
Gastric Cancer
DRUG: S-1|DRUG: LV
Overall Response Rate (ORR), The primary endpoint is overall response rate,which equals the rate of patients with CR+PR., 1 year
Progression free survival (PFS), Progression-free survival (PFS) was determined from the date of treatment to progression or death, 1-1.5 years|Overall survival (OS), Overall survival (OS) was calculated from the date of treatment to death from any cause or the last date of follow-up., 1-2.5 years|Time to treatment failure (TTF), Time to treatment failure (TTF) was determined from the date of treatment to progression, death, refusal or interruption due to adverse events., 1 year|Disease control rate, Disease control rate equals the rate of patients with CR+PR+SD., 1 year|Adverse Events (AEs), All treatment-related adverse events (AEs) were categorized according to the National Cancer Institute's Common Terminology Criteria for Adverse Events., 2 year
Patients enrolled in this study were orally treated with S-1 in doses of 40 mg (body surface area (BSA)\<1.25 m2), 50 mg (1.25≤BSA\<1.50 m2) and 60 mg (BSA≥1.50 m2) b.i.d. on days 1-7 in combination with LV given simultaneously at a ﬁxed dose of 25 mg b.i.d. on days 1-7, followed by a 7 day rest. Treatment courses were repeated every 2 weeks. Treatment was continued until progressive disease (PD), unacceptable toxicity or patient refusal.